-

RIVN SHAREHOLDER ALERT: Robbins LLP Investigates Rivian Automotive, Inc. (RIVN) on Behalf of Shareholders

SAN DIEGO--(BUSINESS WIRE)--The Class: Shareholder rights law firm Robbins LLP is investigating Rivian Automotive, Inc. (NASDAQ: RIVN) and its officers and directors to determine if the Company made false and misleading statements in its Offering Documents in Support of its initial public offering ("IPO").

If you would like more information about our investigation into Rivian Automotive, Inc.'s misconduct, click here.

What is this Investigation is About: Rivian designs and manufactures electric vehicles – the R1T electric pickup truck and R1S electric SUV. Rivian began selling the R1T in September 2021 and planned to begin selling the R1S in December 2021. As of October 31, 2021, Rivian reported "approximately 55,400 R1T and R1S preorders in the United States and Canada from customers who paid a cancellable and fully refundable deposit of $1,000." At the time of its IPO, Rivian planned to produce approximately 1,200 R1Ts and 25 R1Ss by the end of 2021, with the all preorders filled by end of 2023.

Rivian completed its IPO on November 10, 2021, selling shares at $78.00 per share for total proceeds of $11.93 billion. However, unbeknownst to investors, the Registration Statement failed to disclose that Rivian underpriced the R1T and R1S to such a degree that the Company would have to raise prices shortly after the IPO. Subsequently, these price increases would tarnish Rivian's reputation as a trustworthy and transparent Company and would put a significant number of its backlog orders as well as future orders in jeopardy of cancellation. Accordingly, the price of the Company's shares was artificially inflated at the time of the IPO. As Rivian announced its plans to increase its prices, its shares took a hit. Rivian stock now ow trades near $38.00 per share, significantly below the Company's $78.00 IPO price.

Next Steps: If you acquired shares of Rivian Automotive, Inc. pursuant to the Company's IPO, you have legal options. Contact us for more information.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

Contact us to learn more:

Aaron Dumas
(800) 350-6003
adumas@robbinsllp.com
Shareholder Information Form

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against Rivian Automotive, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Aaron Dumas
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Robbins LLP

NASDAQ:RIVN

Release Summary
RIVN SHAREHOLDER INVESTIGATION: Robbins LLP Investigates Rivian Automotive, Inc. (RIVN) on Behalf of Shareholders
Release Versions
$Cashtags

Contacts

Aaron Dumas
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

Erasca, Inc. Class Action Reminder - Robbins LLP Encourages ERAS Stockholders to Contact the Firm for Information About Their Rights  

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Erasca, Inc. (NASDAQ: ERAS) securities between January 14, 2025 and April 26, 2026. Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers.For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call...

ADMA Biologics, Inc. Stock Drop: Robbins LLP Urges Investors to Contact the Firm for Information About the Class Action Against ADMA Biologics, Inc.

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired ADMA Biologics, Inc. (NASDAQ: ADMA) securities between August 9, 2024 and March 25, 2026. ADMA Biologics, Inc. is a biopharmaceutical company that develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. For more information...

VIA Transportation, Inc. Stock Drop: Harmed Investors Should Contact Robbins LLP for Information About Leading the Class Action Against VIA

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Via Transportation, Inc. (NYSE: VIA) in connection with the Company's September 15, 2025 initial public statement ("IPO"). Via Transportation, Inc. provides a platform that transforms global transportation systems into digital networks in the United States, Germany, and internationally.For more information, submit a form, email attorney Aaron D...
Back to Newsroom